Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04048642
Other study ID # STUDY00003764
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2020
Est. completion date February 10, 2022

Study information

Verified date March 2022
Source University of Rochester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a crossover study utilizing a Dietary Approaches to Stop Hypertension (DASH) diet and a whole-food, plant-based diet among subjects with type 2 diabetes who require insulin. Outcomes are short-term changes in insulin requirements and changes in various biomarkers.


Description:

This is a single center, prospective, non-randomized crossover study. The aim of the study is to perform a comprehensive evaluation of factors that may contribute to improvements in glycemic control in obese patients with type 2 diabetes during a plant-based dietary intervention. The primary end point will be the change in total daily insulin requirements during the plant-based dietary intervention period compared against a Dietary Approaches to Stop Hypertension (DASH) diet. Evaluation of insulin requirements will be carried out in three phases of this study: pre-intervention (Phase 1), intervention (Phase 2), and post-intervention (Phase 3). Each phase is 7 days. In addition, investigators plan to evaluate the effects of a plant-based diet on glucose homeostasis by estimating the insulin sensitivity index and beta cell function using weekly sampled oral glucose tolerance tests (oGTT) and will explore if these effects correlate with changes in urinary glucose excretion by using weekly sampled urinary tests. Investigators will also be assessing changes in obesity-related inflammatory biomarkers, stress biomarkers and metabolic markers during the three phases of the study. Lastly, given the current technological advantages in the field of diabetes monitoring, investigators plan to monitor the glycemic excursion curve using a continuous glucose monitor during the complete study.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date February 10, 2022
Est. primary completion date February 10, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults (older than 18 years old) of both genders, of all races and ethnicities. - Pre-existing diagnosis of Type 2 Diabetes Mellitus, as documented in medical records on basal with or without mealtime bolus insulin with no change to total of basal insulin and nutritional baseline insulin dosing > 10% in the 1 month prior to consent and no changes to non-insulin antihyperglycemic medications in the 3 months prior to consent - If on a GLP-1 analog, on a stable dose for at least 3 months prior to the study enrollment - If on an SGLT2 inhibitor, on a stable dose for at least 3 months prior to the study enrollment - BMI of 27 kg/m2 or greater - Most recent HbA1c (within 6 months prior to consent) between 6.5% and 9.5% - Fluent in the English language (education about each diet will be in English) - Willingness and ability to participate in study protocol. - Agreeable to give informed consent. Exclusion Criteria: - Diagnosis of T1DM or type 1.5 diabetes mellitus - History of liver cirrhosis - Impaired renal function (GFR < 45 ml/min) within 6 months prior to consent - History of hyperkalemia (potassium > 5.4 meq/L) within 6 months prior to consent - Use of an insulin pump or expected to start during the study period - Use of warfarin (Coumadin) - Use of daily aspirin 500 mg or more or expected to start during the study period - Use of daily Vitamin C of 1,000 mg or more, unless willing to stop taking 1 week prior to baseline visit and for duration of study - Use of antipsychotics or systemic steroids within 3 months prior to consent - Use of any of the following weight-lowering pharmacotherapy within 3 months prior to consent: phentermine, orlistat, lorcaserin, phentermine/topiramate, bupropion/naloxone - The use of insulin secretagogues including sulfonylureas and glinides within 3 months prior to consent as this may increase the risk of hypoglycemia and alter assessment of daily insulin requirements during the study - The use of illicit drugs, defined as active use or use within 3 months prior to consent. - Engage in high risk alcohol use (defined as more than 4 drinks on any day or more than 14 drinks per week in men and more than 3 drinks on any day or 7 drinks per week in women). - Individuals who are pregnant or breastfeeding or intend to become pregnant during the duration of the study - Individuals who are following a vegetarian or vegan diet at the time of consent - Food allergies or intolerances that will interfere with diet adherence - Lack of access to a full-size refrigerator (required for storage of 3-4 days of prepared study meals) - Active malabsorption disorder, including uncontrolled symptomatic inflammatory bowel disease, or bariatric surgery in the past 1 year

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
DASH
7 days of a DASH diet
Whole-Food, Plant-Based
7 days of a WFPB diet

Locations

Country Name City State
United States UR Medicine/Highland Hospital Nutrition in Medicine Research Center Webster New York

Sponsors (1)

Lead Sponsor Collaborator
University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in total daily insulin requirements 7 Days
Secondary Changes in glucose excursion curve 7 days
Secondary Changes in serum leptin 7 days
Secondary Changes in serum adiponectin 7 days
Secondary Changes in serum C-peptide levels 7 days
Secondary Changes in serum insulin levels 7 days
Secondary Change in lipid panel 7 days
Secondary Change in hsCRP 7 days
Secondary Change in IL-6 7 days
Secondary Change in IL-18 7 days
Secondary Change in TNF-a 7 days
Secondary Change in urinary catecholamines 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2